Influence of different factors (duration of disease, gender, education, patients' history, job and age) in metformin response in type 2 diabetes mellitus patient.

Objective: Aim: This study aims to evaluate how various factors affect various aspects of glycemic control in individuals with type 2 diabetes who are undergoing metformin treatment.

Patients And Methods: Materials and Methods: A cross-sectional study involved 150 participants who met specific criteria, including being aged between 30 and 70, having a type 2 diabetes diagnosis, and using 1000 mg of metformin as the monotherapy for at least three months. Collected data encompassed various measures, such as levels of glycated hemoglobin (HbA1c), fasting blood glucose concentrations, fasting serum insulin levels, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), and insulin sensitivity.

Diet control and BMI impact on Metformin response in type 2 Diabetes mellitus patients.

Objective: Aim: To assess the impact of BMI and diet control on variation in response to metformin monotherapy in Iraqi people with type 2 DM.

Patients And Methods: Materials and Methods: a cross-sectional study included 150 patients who met specific criteria, such as being between 30 and 70 years old, diagnosed with type 2 diabetes, and on a daily dose of 1000 mg metformin as a monotherapy for at least three months. Data collected included body mass index (BMI) and glycemic control parameters such as: glycated hemoglobin (HbA1c) levels, fasting blood glucose levels, fasting serum insulin levels, HOMA-IR, and insulin sensitivity.

The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus.

Background: The response of patients with Type 2 diabetes mellitus (T2DM) to metformin may be a variation because of genetic differences in solute carrier (SLC) transporter proteins and other effect factors, which have an important effect on how metformin is processed in the body and its efficiency for glycaemic control.

Aim: This study was conducted to investigate the impact of certain genetic variants of the organic cation transporter genes OCT3 (SLC22A3 rs12194182 and rs8187722) and MATE2 (SLC47A2 rs12943590) and their association with glycaemic parameters in patients with T2DM who respond poorly to metformin.

Patients And Methods: This cross-sectional study involved 150 Iraqi cases with T2DM who were prescribed a daily dose of (1000 mg/day) metformin for a minimum of 3 months.